Voxelotor | search
Click here to view Voxelotor news from 60+ newspapers.
Bookmark or Share- Systematic Review of Voxelotor: A First‐in‐Class Sickle Hemoglobin ...Voxelotor, a sickle hemoglobin polymerization inhibitor, was approved by the U.S. Food and Drug Administration to treat sickle cell disease (SCD) in November 2019. This article reviews published data...
- Voxelotor - WikipediaVoxelotor, sold under the brand name Oxbryta, was a medication used for the treatment of sickle cell disease. [1] [3] [4] [5] [6] Voxelotor is the first hemoglobin oxygen-affinity modulator. [7] Voxelotor had been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell ...
- Voxelotor: Uses, Interactions, Mechanism of Action - DrugBank OnlineVoxelotor is a drug used to inhibit the polymerization of hemoglobin S, preventing the painful and sometimes lethal vaso-occlusive crises associated with sickle cell disease.
- A Phase 3 Randomized Trial of Voxelotor in Sickle Cell DiseaseVoxelotor is an HbS polymerization inhibitor. In a multicenter, phase 3, double-blind, randomized, placebo-controlled trial, we compared the efficacy and safety of two dose levels of...
- Voxelotor (Oxbryta) Tablets: Uses & Side Effects - Cleveland ClinicVoxelotor treats sickle cell disease. This condition affects your red blood cells, and makes it difficult for hemoglobin to easily pass through your blood vessels. Hemoglobin is the main component of red blood cells.
More
